Scatena Roberto: Difference between revisions
From Bioblast
No edit summary |
m (Gurkina Angelina moved page Scatena R to Scatena Roberto over redirect) ย |
||
(22 intermediate revisions by 8 users not shown) | |||
Line 1: | Line 1: | ||
{{EAGLE | {{EAGLE | ||
|COST= | |COST= Member | ||
|COST WG4= WG4 | |COST WG1= WG1 | ||
|COST WG2= WG2 | |||
|COST WG3= WG3 | |||
|COST WG4= WG4 | |||
|COST Mentor= Mentor | |||
}} | }} | ||
: [[Management_Committee_MitoEAGLE#MC_Members|MC Member]] - [[Management Committee MitoEAGLE]] | |||
{{Person | {{Person | ||
|lastname=Scatena | |lastname=Scatena | ||
|firstname=Roberto | |firstname=Roberto | ||
|title=Prof. PhD | |title=Prof. PhD | ||
|institution= | |institution=[[File:ScatenaR.jpg|right|150px|Roberto Scatena]] Department of Diagnostics and Laboratory Medicine, | ||
ย | |||
Institute of Biochemistry and Clinical Biochemistry, | |||
ย | |||
Polyclinic A. Gemelli - Catholic University, IT | |||
|address=Largo A. Gemelli 8 | |address=Largo A. Gemelli 8 | ||
|area code=00168 | |area code=00168 | ||
|city=Rome | |city=Rome | ||
|country=Italy | |country=Italy | ||
|mailaddress= | |mailaddress=roberto[email protected] | ||
}} | }} | ||
== New Open Access Journal == | |||
:::: Dr. R. Scatena is the editor of 'Cancer Stem Cells'. | |||
{{Labelingperson | {{Labelingperson | ||
|field of research=Basic | |field of research=Basic | ||
}} | }} | ||
ย | |||
== MitoEAGLE Feedback == | |||
:::: ''Specifically, we are studying mitochondrial metabolism in cancer cells. At this aim we are also participating to mt-HPP project, an Italianย consortium whose target is a definition of mitochondrial proteome inย health and disease. Briefly, my specific activity is to compare mitochondrial functionalย status with the mitochondrial proteome picture in different human cellย line. I do think that a "contact" between these two importantย initiatives should be useful for both.'' | |||
ย | |||
:::: ''Moreover, to stress the potentialย translational applications of research on bioenergetics in general and on mitochondria in particular (as also recently highlighted by Paolo Bernardi during EBEC 2016),ย I would like to suggest to beginย to think toย a careful pathophysiological classification of all mitochondriopathies (inborn and acquired, primary and secondary, ECR of metabolic related and so on) to reinforce the concept of a โmitochondrial medicineโ, concept, until now, too often neglected with dramatic consequences.'' - '''[[Scatena R| Scatena Roberto]]''' (2016). | |||
ย | |||
ย | |||
== Participated at == | |||
ย | |||
::::*[[MiP2018/MitoEAGLE Jurmala LV|MitoEAGLE 2018 Jurmala LV]] | |||
::::* [[MitoEAGLE Obergurgl 2017| MitoEAGLE 2017 Obergurgl AT]] | |||
::::* [[MitoEAGLE Barcelona 2017| MitoEAGLE 2017 Barcelona ES]] | |||
::::* [[MitoEAGLE Verona 2016| MitoEAGLE 2016 Verona IT]] | |||
::::* [[IOC44|IOC44 Schroecken AT]] |
Latest revision as of 10:41, 17 March 2020
News and Events | Working Groups | Short-Term Scientific Missions | Management Committee | Members |
COST Action CA15203 (2016-2021): MitoEAGLE
Evolution-Age-Gender-Lifestyle-Environment: mitochondrial fitness mapping
Scatena Roberto
MitoPedia topics: EAGLE
COST: Member COST WG1: WG1 COST WG2: WG2 COST WG3: WG3 COST WG4: WG4 COST Mentor: Mentor
Name | Scatena Roberto, Prof. PhD |
---|---|
Institution | Department of Diagnostics and Laboratory Medicine,
Institute of Biochemistry and Clinical Biochemistry, Polyclinic A. Gemelli - Catholic University, IT |
Address | Largo A. Gemelli 8, 00168 |
City | Rome |
State/Province | |
Country | Italy |
[email protected] | |
Weblink | |
O2k-Network Lab | IT Rome Scatena R |
New Open Access Journal
- Dr. R. Scatena is the editor of 'Cancer Stem Cells'.
Labels:
Field of research: Basic
Publications
Published | Reference | |
---|---|---|
BEC 2020.1 doi10.26124bec2020-0001.v1 | 2020 | Gnaiger E et al โ MitoEAGLE Task Group (2020) Mitochondrial physiology. Bioenerg Commun 2020.1. https://doi.org/10.26124/bec:2020-0001.v1 |
Bottoni 2019 Adv Exp Med Biol | 2019 | Bottoni P, Scatena R (2019) Mitochondrial metabolism in cancer. A tangled topic. Which role for proteomics? Adv Exp Med Biol 1158:1-16. |
Scatena 2019 Curr Med Chem | 2019 | Scatena R, Bottoni P (2019) The tangled mitochondrial metabolism in cancer: An innovative pharmacological approach. Curr Med Chem 27:2106-17. |
Tesori 2015 Sci Rep | 2015 | Tesori V, Piscaglia AC, Samengo D, Barba M, Bernardini C, Scatena R, Pontoglio A, Castellini L, Spelbrink JN, Maulucci G, Puglisi MA, Pani G, Gasbarrini A (2015) The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing. Sci Rep 5:9149. |
Scatena 2012 Adv Exp Med Biol | 2012 | Scatena R, Bottoni P, Giardina B (eds) (2012) Advances in mitochondrial medicine. Adv Exp Med Biol 942:p461. |
Abstracts
Published | Reference | |
---|---|---|
Scatena 2018 MiP2018 | 2018 | No abstract. |
Scatena 2017 Abstract MITOEAGLE Barcelona | 2017 | Mitochondria and cancer stem cells in hepatocarcinoma. An illustrative example of a tangled methodological approach. |
Scatena 2017 MITOEAGLE Obergurgl | 2017 | Cancer stem cell differentiation induced by PPAR ligands. Which role for an inhibition of mitochondrial respiratory chain? |
MitoEAGLE Feedback
- Specifically, we are studying mitochondrial metabolism in cancer cells. At this aim we are also participating to mt-HPP project, an Italian consortium whose target is a definition of mitochondrial proteome in health and disease. Briefly, my specific activity is to compare mitochondrial functional status with the mitochondrial proteome picture in different human cell line. I do think that a "contact" between these two important initiatives should be useful for both.
- Moreover, to stress the potential translational applications of research on bioenergetics in general and on mitochondria in particular (as also recently highlighted by Paolo Bernardi during EBEC 2016), I would like to suggest to begin to think to a careful pathophysiological classification of all mitochondriopathies (inborn and acquired, primary and secondary, ECR of metabolic related and so on) to reinforce the concept of a โmitochondrial medicineโ, concept, until now, too often neglected with dramatic consequences. - Scatena Roberto (2016).